Aimmune Therapeutics (AIMT) Downgraded to “Hold” at Zacks Investment Research

Zacks Investment Research lowered shares of Aimmune Therapeutics (NASDAQ:AIMT) from a buy rating to a hold rating in a research note released on Wednesday.

According to Zacks, “Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company’s characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. “

Several other analysts have also recently issued reports on AIMT. Wedbush reaffirmed an ourperform rating and set a $42.00 price objective on shares of Aimmune Therapeutics in a report on Monday, August 14th. ValuEngine cut Aimmune Therapeutics from a hold rating to a sell rating in a report on Friday, December 1st. BidaskClub cut Aimmune Therapeutics from a hold rating to a sell rating in a report on Friday, August 11th. Piper Jaffray Companies upped their price objective on Aimmune Therapeutics from $38.00 to $60.00 and gave the stock an overweight rating in a report on Tuesday. Finally, Roth Capital began coverage on Aimmune Therapeutics in a report on Monday, November 20th. They set a buy rating and a $60.00 price objective on the stock. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the stock. The company has an average rating of Hold and a consensus price target of $53.80.

Aimmune Therapeutics (NASDAQ AIMT) traded down $0.92 during mid-day trading on Wednesday, reaching $35.36. The company’s stock had a trading volume of 317,300 shares, compared to its average volume of 354,939. Aimmune Therapeutics has a 1-year low of $15.97 and a 1-year high of $38.86.

Aimmune Therapeutics (NASDAQ:AIMT) last posted its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.63) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.72) by $0.09. equities analysts anticipate that Aimmune Therapeutics will post -2.54 earnings per share for the current fiscal year.

In related news, CEO Stephen George Dilly sold 80,110 shares of the stock in a transaction on Wednesday, October 4th. The stock was sold at an average price of $26.23, for a total transaction of $2,101,285.30. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Susan E. Barrowcliffe sold 20,000 shares of the stock in a transaction on Monday, September 25th. The shares were sold at an average price of $25.00, for a total value of $500,000.00. Following the sale, the insider now owns 20,000 shares in the company, valued at approximately $500,000. The disclosure for this sale can be found here. Insiders have sold a total of 274,986 shares of company stock worth $7,533,100 in the last 90 days. 24.56% of the stock is currently owned by insiders.

Large investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC raised its holdings in Aimmune Therapeutics by 10.1% during the 2nd quarter. SG Americas Securities LLC now owns 5,451 shares of the biotechnology company’s stock valued at $112,000 after buying an additional 499 shares during the period. Legal & General Group Plc raised its holdings in Aimmune Therapeutics by 26.6% during the 2nd quarter. Legal & General Group Plc now owns 7,776 shares of the biotechnology company’s stock valued at $160,000 after buying an additional 1,634 shares during the period. Voya Investment Management LLC increased its stake in Aimmune Therapeutics by 31.2% in the second quarter. Voya Investment Management LLC now owns 15,781 shares of the biotechnology company’s stock worth $324,000 after purchasing an additional 3,757 shares during the period. DekaBank Deutsche Girozentrale purchased a new stake in Aimmune Therapeutics in the second quarter worth $333,000. Finally, Citadel Advisors LLC purchased a new stake in Aimmune Therapeutics in the second quarter worth $360,000. Institutional investors own 73.34% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece was reported by Community Financial News and is owned by of Community Financial News. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.com-unik.info/2017/12/07/aimmune-therapeutics-aimt-downgraded-to-hold-at-zacks-investment-research.html.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

What are top analysts saying about Aimmune Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Aimmune Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit